AMAG Pharmaceuticals, Inc.  

(Public, NASDAQ:AMAG)   Watch this stock  
Find more results for AMAG
24.15
-0.05 (-0.21%)
Feb 17 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 23.95 - 24.40
52 week 17.92 - 36.83
Open 24.10
Vol / Avg. 709,710.00/1.74M
Mkt cap 824.46M
P/E     -
Div/yield     -
EPS -0.16
Shares 34.21M
Beta 1.09
Inst. own 121%
Feb 15, 2017
Q4 2016 AMAG Pharmaceuticals Inc Earnings Release (Estimated)
Jan 10, 2017
AMAG Pharmaceuticals Inc at JPMorgan Healthcare Conference Q&A
Jan 10, 2017
AMAG Pharmaceuticals Inc at JPMorgan Healthcare Conference
Nov 29, 2016
AMAG Pharmaceuticals Inc at Bank of America Merrill Lynch America Leveraged Finance Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '16) 2016
Net profit margin -6.96% -0.47%
Operating margin 9.62% 14.82%
EBITD margin - 18.65%
Return on average assets -1.69% -0.10%
Return on average equity -4.52% -0.27%
Employees 552 -
CDP Score - -

Address

1100 Winter St
WALTHAM, MA 02451-1427
United States - Map
+1-617-4983300 (Phone)
+1-617-6491632 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

AMAG Pharmaceuticals, Inc. is a pharmaceutical company. The Company's segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse. It is engaged in the development of Digoxin immune fab, a polyclonal antibody for the treatment of severe preeclampsia in pregnant women. Makena is a drug indicated to reduce the risk of preterm birth in women pregnant with a single baby having a history of singleton spontaneous preterm birth.

Officers and directors

Gino Santini Chairman of the Board
Age: 59
Bio & Compensation  - Reuters
Frank E. Thomas President, Chief Operating Officer
Age: 46
Bio & Compensation  - Reuters
William K. Heiden Chief Executive Officer, Director
Age: 55
Bio & Compensation  - Reuters
Edward Myles CPA Chief Financial Officer, Senior Vice President - Finance, Treasurer
Age: 43
Bio & Compensation  - Reuters
Nicholas Grund Executive Vice President, Chief Commercial Officer
Bio & Compensation  - Reuters
Nathan McBride Senior Vice President - Innovation Architects and Chief Information Officer
Bio & Compensation  - Reuters
Joseph Vittiglio Senior Vice President, General Counsel, Secretary
Age: 43
Bio & Compensation  - Reuters
Todd H. Van Horn General Manager - CBR and Senior Vice President - Consumer Marketing & Sales at AMAG
Bio & Compensation  - Reuters
Tony Casciano Senior Vice President of Sales and Marketing - Hematology and Oncology business
Bio & Compensation  - Reuters
Elizabeth Bolgiano Senior Vice President of Human Resources
Bio & Compensation  - Reuters